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Abstract: Induction of apoptosis by selective BH3-mimet-
ics is currently investigated as a novel strategy for cancer 
treatment. Here, we report that selective BH3-mimetics 
induce apoptosis in a variety of hematological malignan-
cies. Apoptosis is accompanied by severe mitochondrial 
toxicities upstream of caspase activation. Specifically, the 
selective BH3-mimetics ABT-199, A-1331852 and S63845, 
which target BCL-2, BCL-XL and MCL-1, respectively, induce 
comparable ultrastructural changes including mitochon-
drial swelling, a decrease of mitochondrial matrix density 
and severe loss of cristae structure. These shared effects 
on mitochondrial morphology indicate a similar func-
tion of these anti-apoptotic BCL-2 proteins in maintaining 
mitochondrial integrity and function.
Keywords: apoptosis; BCL-2 proteins; BH3-mimetics; 
mitochondria.
Due to their central role in regulating apoptosis, the anti-
apoptotic BCL-2 proteins are promising targets for the 
development of novel anticancer therapeutics (Adams and 
Cory, 2007). To this end, several so-called BH3-mimetics 
have been developed that bind with nanomolar affinities 
to the hydrophobic groove of anti-apoptotic BCL-2 proteins 
(Vogler et al., 2009). By binding and inhibiting anti-apop-
totic BCL-2 proteins like BCL-2, BCL-XL and MCL-1, BH3-
mimetics can induce the activation and oligomerization of 
BAX and/or BAK, which form pores in the outer mitochon-
drial membrane. Although the precise molecular nature 
of these pores is still not fully characterized, it is well 
reported that activation of BAX and/or BAK is sufficient to 
facilitate the release of cytochrome c from the mitochon-
drial intermembrane space into the cytosol and hence 
induce the activation of caspases and apoptosis (Westphal 
et al., 2014). An alternative way for cytochrome c to escape 
from the mitochondrial intermembrane space involves the 
opening of the permeability transition pore (PTP) in the 
inner mitochondrial membrane, which results in mito-
chondrial swelling, loss of cristae structure, rupture of the 
outer mitochondrial membrane and subsequent release 
of pro-apoptotic factors like cytochrome c (Giorgio et al., 
2018).
We previously reported that treatment of chronic 
lymphocytic leukemia cells with either ABT-199 or ABT-
737, a BH3-mimetic inhibiting BCL-2 and BCL-XL, causes 
apoptosis accompanied by mitochondrial swelling, loss of 
cristae structure and rupture of the outer mitochondrial 
membrane, features more commonly associated with the 
opening of the PTP in the inner mitochondrial membrane 
than with BAX/BAK pore formation in the outer mitochon-
drial membrane (Vogler et al., 2008, 2013). In this study, 
we utilized specific and selective inhibitors of either 
BCL-2 (ABT-199) (Souers et  al., 2013), BCL-XL (A-1331852) 
(Leverson et  al., 2015) or MCL-1 (S63845) (Kotschy et  al., 
2016) to investigate the effects of BH3-mimetics on mito-
chondrial morphology during apoptosis in hematologi-
cal malignancies. Treatment with low concentrations of 
ABT-199 induces rapid apoptosis in RIVA (diffuse large 
B-cell lymphoma, DLBCL) as well as MAVER-1 (mantle 
aKristina Henz and Aoula Al-Zebeeby: These authors contributed 
equally to this work.
*Corresponding author: Meike Vogler, Institute for Experimental 
Cancer Research in Pediatrics, Goethe-University Frankfurt, 
Komturstr. 3a, D-60528 Frankfurt/Main, Germany,  
e-mail: m.vogler@kinderkrebsstiftung-frankfurt.de
Kristina Henz: Institute for Experimental Cancer Research in 
Pediatrics, Goethe-University Frankfurt, Komturstr. 3a, D-60528 
Frankfurt/Main, Germany
Aoula Al-Zebeeby, Gerald M. Cohen and Shankar Varadarajan: 
Department of Molecular and Clinical Cancer Medicine and 
Pharmacology, Institute of Translational Medicine, University of 
Liverpool, Liverpool, UK
Marion Basoglu: Department of Biology, Goethe-University 
Frankfurt, Frankfurt, Germany
Simone Fulda: Institute for Experimental Cancer Research in 
Pediatrics, Goethe-University Frankfurt, Komturstr. 3a, D-60528 
Frankfurt/Main, Germany; German Cancer Consortium (DKTK), 
Heidelberg, Germany; and German Cancer Research Center (DKFZ), 
Heidelberg, Germany
Bereitgestellt von | Universitaetsbibliothek Frankfurt/Main
Angemeldet
Heruntergeladen am | 16.07.18 12:01
2      K. Henz et al.: Mitochondrial toxicities of BH3-mimetics
cell lymphoma) cells as demonstrated by externalization 
of phosphatidylserine (PS) in the cell membrane of the 
apoptotic cells (Figure 1A). In line with an activation of the 
intrinsic apoptotic pathway, exposure to BH3-mimetics 
also induced simultaneous loss of mitochondrial mem-
brane potential (Figure 1B). To investigate whether expo-
sure to ABT-199 also resulted in ultrastructural changes, 
upstream and/or independent of caspase activation and 
subsequent cleavage of cellular targets, we treated RIVA 
and MAVER-1 with ABT-199 in the presence of the caspase 
inhibitor z-VAD.fmk before performing transmission elec-
tron microscopy. For these experiments, z-VAD.fmk was 
included as we had previously shown cell death induced 
by ABT-199 to be caspase-mediated (Vogler et al., 2008), 
and in these experiments were aiming to investigate only 
cellular effects that were induced upstream of caspase 
activation. As anticipated, in comparison to untreated 
control cells, cells treated with ABT-199 in the presence 
of z-VAD.fmk exhibit no overall change in nuclear or cel-
lular morphology (data not shown). Mitochondria in the 
untreated control cells possess intact outer and inner 
membranes with well-defined cristae, characteristic of 
healthy mitochondria with structural and functional 
integrity (Figure 1C and D). In contrast, cells treated with 
ABT-199 exhibit strikingly swollen mitochondria, with 
a significant loss of mitochondrial matrix density and 
a ruptured outer mitochondrial membrane, suggesting 
that inhibition of BCL-2 resulted in marked mitochondrial 
ultrastructural changes, upstream and/or independent of 
the other hallmarks of apoptosis (Figure 1E and F).
To investigate the effect of BCL-XL inhibition on mito-
chondrial structural changes, RCK8 (DLBCL) and K562 
(chronic myeloid leukemia) cells that primarily rely on 
BCL-XL for survival were chosen (Figure 2A and B). RCK8 
cells exhibit a mixed mitochondrial morphology, with 
some cells displaying dark mitochondria indicative of 
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Figure 1: Mitochondrial perturbations induced by ABT-199 in BCL-2 dependent cells.
(A and B) RIVA and MAVER-1 cells were exposed to 10 nm ABT-199 (Selleck Chemicals, Houston, TX, USA) for 4 h before analysis of apoptosis 
by PS exposure and binding of AnnexinV-FITC followed by flow cytometry (A) or loss of mitochondrial membrane potential (B) as measured 
by staining with 50 nm tetramethylrhodamine methyl ester (TMRM, Sigma, Deisenhofen, Germany) and flow cytometry. Flow cytometry was 
performed using FACSCanto II (BD Biosciences, Heidelberg, Germany). Data presented are mean plus standard deviation (n = 3 for RIVA and 
n = 4 for MAVER-1). Asterisks indicate statistical significance as analyzed using Student’s t-test with two-tailed distribution, two-sample, 
unequal variance (*p < 0.05; **p < 0.01; ***p < 0.001). (C and E) RIVA cells were either left untreated (C) or exposed to 10 nm ABT-199 for 4 h 
in the presence of 25 μm z-VAD.fmk (Bachem, Heidelberg, Germany) (E) before fixation in 2.5% glutaraldehyde and processing for electron 
microscopy. (D and F) MAVER-1 cells were either left untreated (D) or exposed to 10 nm ABT-199 for 2 h in the presence of z-VAD.fmk (25 μm) 
(F) before fixation in 2.5% glutaraldehyde and processing for electron microscopy.
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higher matrix density, and other cells displaying larger 
and brighter mitochondria with less dense mitochondrial 
matrix and regular cristae structures (Figure 2C). In cells 
exposed to A-1331852, the mitochondrial cristae structure 
is largely lost and mitochondria appear smaller, indica-
tive of mitochondrial fragmentation or fission. Rupture 
of the outer mitochondrial membrane is also evident in 
some swollen mitochondria (Figure 2E). Similarly, the 
well-defined mitochondrial cristae in the untreated K562 
cells are completely lost following exposure to A-1331852, 
indicative of severe mitochondrial toxicity (Figure 2D 
and F). Interestingly, BCL-XL has recently been described 
to maintain a functional mitochondrial network, and 
BCL-XL knockout murine embryonic fibroblasts displayed 
fragmented mitochondria as assessed by fluorescence 
microscopy (Pfeiffer et al., 2017).
Next, we investigated the effects of a specific and 
potent inhibitor of MCL-1, S63845, whose derivative, 
MIK665 is currently being investigated in clinical trials 
for the treatment of multiple myeloma and acute myeloid 
leukemia (NCT02979366 and NCT02992483). Using 
SUDHL10 DLBCL cells that depend primarily on MCL-1 for 
survival, we observe a rapid induction of intrinsic apop-
tosis upon exposure to S63845 accompanied by a loss of 
mitochondrial membrane potential (Figure 3A and B). 
SUDHL10 cells contain large clearly defined bright mito-
chondria with regular cristae structures. Exposure to 
S63845 induces a prominent loss of cristae structures and 
rupture of the outer mitochondrial membranes in some 
affected mitochondria. Inhibition of MCL-1 by S63845 also 
induces more fragmented, smaller mitochondria with 
vesicular structures rather than the well-defined cristae 
structures, in line with our previous report on mitochon-
drial fragmentation induced by the related MCL-1 inhibi-
tor, A-1210477 (Milani et al., 2017). Interestingly, a similar 
mitochondrial phenotype was previously reported in 
MCL-1 knockout murine embryonic fibroblasts (Percia-
valle et  al., 2012). In that study, MCL-1 deletion induced 
the appearance of punctate mitochondria, the loss of the 
tubular mitochondrial network as well as ultrastructural 
defects including defective cristae harboring balloon-like, 
vesicular structures.
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Figure 2: Mitochondrial perturbations induced by A-1331852 in BCL-XL dependent cells.
(A and B) RCK8 and K562 cells were exposed to A-1331852 (Selleck Chemicals) (3 nm for RCK8 and 10 nm for K562 cells) for before analysis 
of apoptosis by PS exposure and binding of AnnexinV-FITC (A) or loss of mitochondrial membrane potential (B) as measured by staining with 
TMRM and flow cytometry. Data presented are mean plus standard deviation (n = 4). Asterisks indicate statistical significance as analyzed 
using Student’s t-test (*p < 0.05; **p < 0.01; ***p < 0.001) (C and E) RCK8 cells were either left untreated (C) or exposed to 3 nm A-1331852 for 
4 h in the presence of z-VAD.fmk (25 μm) (E). (D and F) K562 cells were either left untreated (D) or exposed to 10 nm A-1331852 for 2 h in the 
presence of z-VAD.fmk (25 μm) (F) before fixation in 2.5% glutaraldehyde and processing for electron microscopy.
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Although mitochondria are involved in apoptotic and 
necrotic forms of cell death, the molecular characteris-
tics of apoptosis and necrosis are very different. While 
classical apoptosis involves the formation of a BAX/BAK 
mediated pore in the outer mitochondrial membrane, 
necrotic cell death is facilitated by opening of the PTP, a 
calcium-dependent channel connecting inner and outer 
mitochondrial membranes (Kroemer et  al., 2007). Upon 
PTP opening, small solutes and water move osmotically 
into the mitochondrial matrix, thus causing swelling and 
rupture of the outer mitochondrial membrane (Bernardi 
et al., 2006). Our data showing swelling of mitochondria 
upon exposure to selective BH3-mimetics indicate that 
BCL-2, BCL-XL and MCL-1 all play a role in the regulation of 
PTP opening. This conclusion is supported by the finding 
that also BAX and BAK can be involved in the formation 
of the PTP (Karch et al., 2013), thus providing a molecu-
lar link between the anti-apoptotic BCL-2 proteins and 
PTP opening.
In addition to swelling we observe a prominent 
loss of cristae structures upon exposure to BH3-mimet-
ics. A large fraction of mitochondrial cytochrome c is 
located and sequestered in the cristae, and hence effi-
cient release of cytochrome c requires the opening of 
cristae structures (Scorrano et  al., 2002). Opening of 
mitochondrial cristae junctions is regulated by the 
dynamin-related protein optic atrophy 1 (OPA1) (Frezza 
et  al., 2006). Interestingly, several reports have linked 
the BCL-2 family to cristae opening, where BH3-only 
proteins and/or active BAX/BAK are required to facili-
tate OPA1  mediated cristae opening and subsequent 
cytochrome c release (Yamaguchi et  al., 2008; Landes 
et al., 2010).
Taken together, we describe a common function 
of the anti-apoptotic BCL-2 proteins BCL-2, BCL-XL and 
MCL-1 in maintaining mitochondrial integrity and cristae 
structures, which can be antagonized by using selective 
BH3-mimetics and occurs during BH3-mimetic induced 
apoptosis in malignant hematological cells.
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